HOME >> MEDICINE >> NEWS
NHLBI research highlights at American Heart Association's scientific sessions

own in angiography. These associations are independent of cardiac risk factors. The scientists found no similar relationship in premenopausal women. NHLBI spokesperson: George Sopko, MD.; WISE Investigator: C. Noel Bairey Merz, Cedars Sinai Medical Center, LA. Contact Dr. Bairey Merz at Noel.BaireyMerz@cshs.org.

*Importance of socioeconomic status in predicting heart attack and cardiovascular death in women. (Embargoed until 12:00 noon Central Time (1:00 p.m. ET), Monday, November 14.) The strong relationship between socioeconomic status (SES) and cardiovascular disease is known. However, the impact of SES on heart attacks and cardiovascular death in women is complex, as women are more likely to live in poverty than men. To help clarify this complex relationship, Women's Ischemia Syndrome Evaluation (WISE) study investigators explored the relative contributions of SES factors compared to traditional heart disease risk factors on heart attack and death in 819 women. Through exams, medical histories and records, questionnaires, and angiography, the scientists obtained extensive information on such SES factors as ethnicity, marital status, highest level of education, retirement status, income, and health insurance coverage. During the 5 years of follow-up, there were 92 deaths or heart attacks. In general, women with the following characteristics were more likely to have negative heart-related outcomes: less than a 9th grade education, being African American, Hispanic, Asian, or American Indian, on public insurance, unmarried, with annual household income less than $20,000, disabled, employed less than full time, and in service or technical jobs. An evaluation of all SES factors revealed that insurance status and income were the single greatest predictors of a participant's cardiovascular status. When the scientists controlled for severity of coronary artery disease as shown on angiography, income rema
'"/>

Contact: NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung, and Blood Institute
15-Nov-2005


Page: 1 2 3 4

Related medicine news :

1. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
2. NHLBI awards 12 Womens Health Initiative contracts
3. NHLBI and NIH statements on totally implanted permanent artificial heart
4. NHLBI offers complete guide to physical activity for a healthy heart
5. NHLBI media availability: Low-fat dietary pattern and weight change
6. MGH named by NHLBI as Specialized Center for Cell-Based Therapy for Heart, Lung and Blood Diseases
7. New NHLBI-sponsored study shows programs can teach children to eat healthier
8. 1 of 2 pediatric kidney disease research centers in world established
9. Stanford researchers find culprit in aging muscles that heal poorly
10. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
11. Indiana University Imaging Center receives $6M grant for kidney research

Post Your Comments:
(Date:6/19/2013)... A University of Iowa study reveals significant disparities ... for completing substance abuse treatment programs. Moreover, these ... , "Our findings suggest that for most states ... professor of psychiatry and biostatistics. "There are strong ... able to complete substance abuse treatment programs successfully, ...
(Date:6/19/2013)... Nearly 70 percent of Americans are on ... half take two, Mayo Clinic researchers say. Antibiotics, ... their study found. Twenty percent of patients are ... the findings, published online in the journal ... audio and video of Dr. Jennifer St. Sauver ...
(Date:6/19/2013)... pharmaceutical companies, along with the Japanese government and ... commitment to bolster Japan,s contribution to global health ... Fund), at a press conference held as a ... on African Development (TICAD V). , Representatives from ... of Health, Labour and Welfare, the Ministry of ...
(Date:6/19/2013)... PREFERRED Therapy Providers, Inc. (PREFERRED) has announced an ... a new Medicare Advantage Plan for PREFERRED’s provider network ... Arizona counties. The agreement takes effect in two stages: ... and Maricopa and Pima counties will become effective on ... of WellCare of Arizona has Medicare Advantage plans in ...
(Date:6/19/2013)... Guests at the Residence Inn Scottsdale Paradise Valley ... don’t go to bed or rise early thanks to a ... , Crafty travelers will have a little extra change ... Scottsdale Paradise Valley hotel’s Book Early and Save Up ... advance notice, guests can enjoy the year-round Scottsdale sunshine in ...
Breaking Medicine News(10 mins):Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Nearly 7 in 10 Americans are on prescription drugs, Mayo Clinic study finds 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3Health News:PREFERRED Therapy Providers, Inc. and WellCare of Arizona Finalize Their Agreement to Offer Medicare Advantage Plan to PREFERRED's Arizona Provider Network 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4
(Date:6/19/2013)... June 19, 2013   Voices Against Brain Cancer ... cure for brain cancer, today announced that it has ... support the clinical investigation of Toca 511 & Toca ... glioma brain cancer (Grade 3 or Grade 4).  Tocagen ... for advanced cancer, with an initial focus on brain ...
(Date:6/19/2013)...   Nektar Therapeutics (Nasdaq: NKTR ) ... (HAL) study for NKTR-181, a first-in-class, opioid analgesic ... This slow rate of entry is designed to reduce the ... to current opioid analgesics. 1 In the study data ... placebo in "drug liking" and "feeling high" scores and had ...
(Date:6/19/2013)... , June 19, 2013 NeuroDerm, ... study in volunteers, and preliminary results from a phase ... presented at the 2013 International Congress of Parkinson,s Disease ... drug formula under development for continuous administration through a ... plasma concentrations. ND0612 has been shown in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 2Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 3Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 4Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 5Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 6Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 7Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 8Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence 9NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6
Cached News: